Uniting Wealth Partners LLC Acquires New Holdings in Johnson & Johnson $JNJ

Uniting Wealth Partners LLC bought a new position in Johnson & Johnson (NYSE:JNJ) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 5,056 shares of the company’s stock, valued at approximately $938,000.

A number of other hedge funds also recently made changes to their positions in the business. SOA Wealth Advisors LLC. raised its stake in Johnson & Johnson by 0.7% during the 3rd quarter. SOA Wealth Advisors LLC. now owns 7,392 shares of the company’s stock valued at $1,371,000 after acquiring an additional 53 shares in the last quarter. Ethos Financial Group LLC increased its holdings in shares of Johnson & Johnson by 0.6% during the third quarter. Ethos Financial Group LLC now owns 9,110 shares of the company’s stock valued at $1,689,000 after purchasing an additional 53 shares during the period. Heritage Oak Wealth Advisors LLC raised its stake in shares of Johnson & Johnson by 3.5% during the third quarter. Heritage Oak Wealth Advisors LLC now owns 1,639 shares of the company’s stock valued at $304,000 after purchasing an additional 55 shares in the last quarter. Investor s Fiduciary Advisor Network LLC lifted its holdings in Johnson & Johnson by 0.8% in the third quarter. Investor s Fiduciary Advisor Network LLC now owns 6,905 shares of the company’s stock worth $1,280,000 after purchasing an additional 55 shares during the period. Finally, TPG Advisors LLC grew its position in Johnson & Johnson by 3.5% in the 3rd quarter. TPG Advisors LLC now owns 1,628 shares of the company’s stock valued at $302,000 after buying an additional 55 shares in the last quarter. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Trading Down 0.5%

Shares of NYSE:JNJ opened at $243.37 on Friday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 0.80 and a current ratio of 1.03. The stock has a market capitalization of $586.51 billion, a price-to-earnings ratio of 22.02, a PEG ratio of 2.36 and a beta of 0.35. Johnson & Johnson has a 1-year low of $141.50 and a 1-year high of $246.35. The company has a 50 day moving average price of $217.25 and a 200 day moving average price of $196.59.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Saturday, January 31st. The company reported $2.46 EPS for the quarter. The company had revenue of $24.28 billion during the quarter. Johnson & Johnson had a return on equity of 33.04% and a net margin of 28.46%. On average, research analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Tuesday, February 24th will be given a $1.30 dividend. The ex-dividend date is Tuesday, February 24th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.1%. Johnson & Johnson’s dividend payout ratio (DPR) is 47.06%.

Analyst Ratings Changes

A number of research firms have commented on JNJ. Loop Capital set a $220.00 price target on shares of Johnson & Johnson in a research report on Tuesday, January 27th. Daiwa Securities Group raised their price objective on shares of Johnson & Johnson from $203.00 to $237.00 and gave the company an “outperform” rating in a research note on Thursday, January 29th. Royal Bank Of Canada upped their target price on Johnson & Johnson from $240.00 to $255.00 and gave the stock an “outperform” rating in a research report on Tuesday, February 3rd. HSBC increased their price target on Johnson & Johnson from $240.00 to $265.00 and gave the company a “buy” rating in a research note on Friday, January 30th. Finally, Guggenheim boosted their price objective on Johnson & Johnson from $227.00 to $240.00 and gave the stock a “buy” rating in a research note on Friday, January 23rd. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and eight have issued a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $233.73.

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.